Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5.9Revenue $M4.4Net Margin (%)-1,811.2Z-Score-1,872.9
Enterprise Value $M5.8EPS $-1,300.0Operating Margin %-423.2F-Score3
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-1,658.3Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0.0Cash flow > EarningsY
Price/Sales0.15-y EBITDA Growth Rate %0Current Ratio0.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-1,514.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0.0ROI % (ttm)0Gross Margin Increase y-yY

Gurus Latest Trades with ACCP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

ACCP is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ACCP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ayer Capital Management, LP10% Owner 2012-06-29Sell82$1425-99.98 view
Ayer Capital Management, LP10% Owner 2012-05-15Sell57$1675-99.99 view

Press Releases about ACCP :

    Quarterly/Annual Reports about ACCP:

    News about ACCP:

    Articles On GuruFocus.com
    Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID Dec 17 2008 

    More From Other Websites
    PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Oct 24 2014
    PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New... Oct 24 2014
    PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 23 2014
    PLASMATECH BIOPHARMACEUTICALS INC Financials Sep 25 2014
    PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 24 2014
    Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And... Sep 22 2014
    ACCESS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 14 2014
    Access Pharmaceuticals Awarded Japan Patent For MuGard And ProctiGard Aug 14 2014
    Access Pharmaceuticals Announces European License Agreement With Norgine Aug 07 2014
    Access Pharmaceuticals Featured On OncLive.com Jul 30 2014
    Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance For ProctiGard™ Jul 22 2014
    Access Pharmaceuticals Awarded Hong Kong Patent For MuGard Jul 08 2014
    ACCESS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 16 2014
    ACCESS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 12 2014
    Access Pharmaceuticals MuGard Selected For Cover Article In The Print Edition Of The Journal Cancer May 01 2014
    Positive Results Of MuGard Study In Erosive Oral Lichen Planus Presented At International Oral... Apr 15 2014
    Access Pharmaceuticals Provides Update On Development Of LexaGard, A Proprietary Formulation Of... Apr 08 2014
    Access Pharmaceuticals Provides Strategic Update On Mucoadhesive Polymer Hydrogel Technology Apr 01 2014
    ACCESS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 26 2014
    Access Pharmaceuticals Cobraxane™ Offers Enhanced Tumor Growth Inhibition In Tumor Models Mar 26 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK